Collectively, our data demonstrate for the first time that inhibition of JNK3 phosphorylation by PBM treatment is powerfully effective in attenuating synaptic dysfunction and reducing multiple neuropathologies associated with AD, suggesting that PBM has potential therapeutic value in impeding AD progression, which is likely achieved by regulating JNK3. The gene discussed is MAPK10; the disease is Alzheimer disease.